Zynerba Pharmaceuticals says results of Phase 2 BELIEVE open-label study of Zygel described as positive in medical journalProactive Investors • 09/07/21
Zynerba Pharmaceuticals Inc says results of Phase 2 BELIEVE open-label study of Zygel described as positive in medical journalProactive Investors • 09/07/21
Zynerba Pharmaceuticals to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewsWire • 09/02/21
Zynerba Pharmaceuticals stock “presents a potentially significant opportunity for patient investors,” says Canaccord GenuityProactive Investors • 08/23/21
Zynerba Pharmaceuticals flush with $85.8M in 2Q to fund pivotal trials of its flagship Zygel CBD gelProactive Investors • 08/09/21
Zynerba Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational HighlightsGlobeNewsWire • 08/09/21
Zynerba Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth ConferenceGlobeNewsWire • 08/04/21
Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Virtual Healthcare ConferenceGlobeNewsWire • 07/07/21
Zynerba Pharmaceuticals Presents Sleep Data from Study of Zygel™ in Children and Adolescents with Both Developmental and Epileptic Encephalopathies (DEE) and Autism Spectrum Disorder (ASD) at the Associated Professional Sleep Societies SLEEP 2021 Annual MGlobeNewsWire • 06/11/21
Zynerba Pharmaceuticals Announces Acceptance of Poster at the Associated Professional Sleep Societies SLEEP 2021 Annual MeetingGlobeNewsWire • 06/04/21
Zynerba Pharmaceuticals Announces Presentation of Efficacy and Safety Findings in Children and Adolescents with Autism Spectrum Disorder (ASD) and Related Disorders at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual MeetingGlobeNewsWire • 06/03/21
Zynerba Pharmaceuticals Announces Acceptance of Poster at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual MeetingGlobeNewsWire • 05/27/21
Zynerba Pharmaceuticals to Present at the Jefferies Virtual Healthcare ConferenceGlobeNewsWire • 05/26/21
Zynerba says its fully funded well into 2024; lays out plans for Zygel RECONNECT trial for Fragile X patientsProactive Investors • 05/12/21
Zynerba Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational HighlightsGlobeNewsWire • 05/12/21
Zynerba receives FDA guidance on confirmatory Phase 3 trial of Zygel in patients with Fragile X syndromeProactive Investors • 05/05/21
Zynerba presents two posters on Zygel at the Society of Biological Psychiatry 2021 Virtual MeetingProactive Investors • 04/29/21